Latest Breaking News On - Cutaneous lupus erythematosus disease area - Page 1 : vimarsana.com

Could Innate Immune Dysfunction Drive Lupus?

Japanese researchers open new front in SLE therapy

John geverYoshiya tanakaEnvironmental healthUniversity of occupationalCutaneous lupus erythematosus disease areaSeverity indexPhysician global assessmentManaging editor

Novel Lupus Approach Yields Mixed Results in Early Trial

Hints of benefit seen in patients with more active disease

United statesJames posadaJohn geverBritish isles lupus assessment groupResolve therapeuticsCutaneous lupus erythematosus disease areaSeverity indexLupus scienceActivity indexManaging editorSci med

Emerging Therapies Foretell New Era for Cutaneous Disorders

Analogous to the early 2000s when treatment options for psoriasis jumped, the same may be true now for treating cutaneous autoimmune disorders.

United statesAnthony fernandezDrug administrationAmerican academy of dermatologyCleveland clinicCutaneous lupus erythematosus disease areaSeverity indexCutaneous dermatomyositis disease areaNew england journalAmerican academySystemic lupus erythematosus sle erythaematosusCutaneous lupus erythematosus erythaematosusBiologic therapyInterferon betaFn betaInterferon beta

Galapagos NV: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

Galapagos NV: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Region flamandeSandra cauwenberghsVan gijselDaniele dambrosioMarieke vermeerschBritish isles lupus assessment groupExchange commissionComposite lupus assessmentCutaneous lupus erythematosus disease areaSeverity index activityLupus low disease activity stateDanieled ambrosioTherapeutic area head immunologyAktien sie

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases.

Region flamandeDaniele dambrosioMarieke vermeerschSandra cauwenberghsVan gijselBritish isles lupus assessment groupExchange commissionComposite lupus assessmentCutaneous lupus erythematosus disease areaSeverity index activityLupus low disease activity stateDanieled ambrosioTherapeutic area head immunology